Literature DB >> 19997690

Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?

Lukasz Matusiak1, Andrzej Bieniek, Jacek C Szepietowski.   

Abstract

Hidradenitis suppurativa (HS) is a recurrent, debilitating suppurative skin disease. Nowadays the major challenge is the choice of optimal treatment. Many conservative therapies seem to have only a supportive character and do not prevent progression of the disease. Early surgical intervention with complete excision of the involved areas is still considered to be the most efficient therapy, but anti-tumour necrosis factor (TNF)-alpha agents may offer a possible non-surgical treatment. The aim of this study was to determine the serum concentration of TNF-alpha and its probable alterations during the disease process in patients with HS. Analysis of TNF-alpha serum concentration in 54 individuals with HS revealed significantly higher levels than in the sera of healthy controls (p = 0.006). To the best of our knowledge, this is the first report of increased TNF-alpha serum concentration in patients with HS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19997690     DOI: 10.2340/00015555-0749

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  31 in total

Review 1.  [Hidradenitis suppurativa/acne inversa: An update].

Authors:  J Kirschke; S Hessam; F G Bechara
Journal:  Hautarzt       Date:  2015-06       Impact factor: 0.751

2.  Association of Birth Weight, Childhood Body Mass Index, and Height With Risk of Hidradenitis Suppurativa.

Authors:  Astrid-Helene Ravn Jørgensen; Julie Aarestrup; Jennifer L Baker; Simon Francis Thomsen
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

3.  Overall and Subgroup Prevalence of Crohn Disease Among Patients With Hidradenitis Suppurativa: A Population-Based Analysis in the United States.

Authors:  Amit Garg; Jessica Hundal; Andrew Strunk
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

4.  Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa.

Authors:  Sarah Reddy; Andrew Strunk; Gregor B E Jemec; Amit Garg
Journal:  JAMA Dermatol       Date:  2020-01-01       Impact factor: 10.282

5.  Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease.

Authors:  Alexis J Lukach; Melissa I Saul; Laura K Ferris; Jason M Swoger
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

6.  Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa.

Authors:  Sarah Reddy; Andrew Strunk; Amit Garg
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

7.  Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota.

Authors:  Siddhant Yadav; Siddharth Singh; Jithinraj Edakkanambeth Varayil; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; Mark Denis P Davis; David A Wetter; Jean-Frederic Colombel; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2015-05-05       Impact factor: 11.382

Review 8.  Hidradenitis suppurativa.

Authors:  Robert Sabat; Gregor B E Jemec; Łukasz Matusiak; Alexa B Kimball; Errol Prens; Kerstin Wolk
Journal:  Nat Rev Dis Primers       Date:  2020-03-12       Impact factor: 52.329

9.  Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn's Disease?

Authors:  Rodrigo Fedatto Beraldo; Mariana Barros Marcondes; Julio Pinheiro Baima; Jaqueline Ribeiro Barros; Madhoor Ramdeen; Rogerio Saad-Hossne; Ligia Yukie Sassaki
Journal:  Clin Exp Gastroenterol       Date:  2020-08-19

10.  Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Jing-Wun Lu; Yu-Wen Huang; Tai-Li Chen
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.